0001171843-20-001357.txt : 20200227 0001171843-20-001357.hdr.sgml : 20200227 20200227184827 ACCESSION NUMBER: 0001171843-20-001357 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200225 FILED AS OF DATE: 20200227 DATE AS OF CHANGE: 20200227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blanchard Cheryl R CENTRAL INDEX KEY: 0001326530 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14027 FILM NUMBER: 20664647 MAIL ADDRESS: STREET 1: C/O ZIMMER, INC. STREET 2: P.O. BOX 708 CITY: WARSAW STATE: IN ZIP: 46580 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Anika Therapeutics, Inc. CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043145961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: (781) 457-9000 MAIL ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA THERAPEUTICS INC DATE OF NAME CHANGE: 19970114 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 4 1 ownership.xml X0306 4 2020-02-25 0 0000898437 Anika Therapeutics, Inc. ANIK 0001326530 Blanchard Cheryl R 32 WIGGINS AVENUE BEDFORD MA 01730 1 0 0 0 Restricted Stock Unit 0.00 2020-02-25 4 A 0 4231 0 A Common Stock 4231 4231 D These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The units shall vest in full and settle as of the earlier of (i) immediately prior to the end of the Term, so long as the Term does not end as the result of Dr. Blanchard's election to terminate her employment, and (ii) February 25, 2021, so long as Dr. Blanchard continues to serve on the Company's Board of Directors as of such date. Dr. Blanchard was recently appointed as the Company's interim Chief Executive Officer (CEO). "Term" is defined as Dr. Blanchard's employment as the Company's interim CEO ending on the earliest of (a) the effective date of the appointment by the Company of a permanent CEO, (b) August 7, 2020, (c) a Change in Control as defined in the Company's 2017 Omnibus Incentive Plan, and (d) such date as of which either the Company or Dr. Blanchard elect to terminate her employment as interim CEO. /s/ Cheryl R. Blanchard 2020-02-27